A promising new drug may offer fresh hope to millions of people living with one of the fastest-growing liver diseases in the world.
Researchers at the University of California San Diego School of Medicine have reported encouraging results from a clinical trial testing an experimental treatment called ION224.
The findings, published in The Lancet, suggest the drug may help reduce liver damage by targeting one of the root causes of the disease rather than simply treating its symptoms.
The condition being studied is known as metabolic dysfunction-associated steatohepatitis, or MASH. It is a serious form of fatty liver disease that is closely linked to obesity, type 2 diabetes, insulin resistance, and other metabolic health problems.
Many people with MASH do not realize they have the condition because symptoms often develop slowly or may not appear until significant liver damage has already occurred.
The disease begins when excess fat accumulates inside liver cells. Over time, this buildup can trigger inflammation and injury within the liver. As the damage continues, scar tissue forms, a process known as fibrosis.
In severe cases, fibrosis can progress to cirrhosis, liver failure, or liver cancer. Once advanced liver damage develops, treatment options become much more limited and may eventually require a liver transplant.
Scientists have been searching for better treatments because fatty liver disease has become a major global health concern. Researchers estimate that roughly one in four adults worldwide may have some form of fatty liver disease. In the United States alone, more than 100 million people are believed to be affected.
Unlike many existing treatments, ION224 was designed to directly target a biological process that contributes to fat accumulation in the liver. The drug works by blocking an enzyme called DGAT2. This enzyme helps the liver produce and store fat.
By reducing DGAT2 activity, researchers hope to stop fat from building up inside liver cells and prevent the chain of events that leads to inflammation and scarring.
The Phase IIb clinical trial enrolled 160 adults with MASH and mild to moderate liver fibrosis. Participants were randomly assigned to receive monthly injections of ION224 at various doses or a placebo for 51 weeks. Throughout the study, researchers monitored changes in liver health and looked for signs of improvement.
The results were encouraging. Patients receiving the highest dose of ION224 experienced some of the greatest benefits. About 60 percent showed meaningful improvements in liver health compared with those who received placebo treatment.
Researchers observed reductions in liver inflammation and fibrosis, suggesting the drug may help slow or even reverse some aspects of liver damage.
An especially important finding was that the benefits appeared to occur even without major weight loss. Many current approaches to treating MASH focus heavily on reducing body weight.
While weight loss remains an important goal for many patients, not everyone is able to achieve or maintain substantial weight reductions. The fact that ION224 appeared to improve liver health independently of weight loss suggests it could eventually become a valuable addition to existing treatment strategies.
The researchers also reported that the drug was generally well tolerated. No serious side effects directly linked to the medication were observed during the trial. In addition, ION224 appeared to avoid certain problems seen with other drugs that target liver fat production, including potentially harmful increases in blood triglyceride levels.
Scientists are particularly excited because this is the first antisense therapy targeting DGAT2 to demonstrate improvements in both liver inflammation and fibrosis in patients with MASH. Antisense therapies work by interfering with genetic instructions inside cells, helping reduce the production of specific proteins involved in disease processes.
The findings also highlight the growing interest in combination treatments. In the future, doctors may combine liver-targeted medications like ION224 with drugs that promote weight loss, improve insulin sensitivity, or address other metabolic risk factors.
Source: University of California San Diego School of Medicine.
